Brainstorm Cell Therapeutics (BCLI)
OTHER OTC:BCLI
Total Valuation
Brainstorm Cell Therapeutics has a market cap or net worth of $10.48M. The enterprise value is $10.66M.
Market Cap$10.48M
Enterprise Value$10.66M
Share Statistics
Brainstorm Cell Therapeutics has 11,034,775 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding11,034,775
Owned by Insiders―
Owned by Institutions1.32%
Financial Efficiency
Brainstorm Cell Therapeutics’s return on equity (ROE) is -1.00 and return on invested capital (ROIC) is 0.00%.
Return on Equity (ROE)-1.00
Return on Assets (ROA)14.42
Return on Invested Capital (ROIC)0.00%
Return on Capital Employed (ROCE)0.00
Revenue Per Employee26.04K
Profits Per Employee-381.74K
Employee Count27
Asset Turnover0.98
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Brainstorm Cell Therapeutics is ―. Brainstorm Cell Therapeutics’s PEG ratio is 0.00.
PE Ratio―
PS Ratio0.00
PB Ratio0.00
Price to Fair Value0.00
Price to FCF0.00
Price to Operating Cash Flow-1.18
PEG Ratio0.00
Income Statement
In the last 12 months, Brainstorm Cell Therapeutics had revenue of 703.00K and earned 10.31M in profits. Earnings per share was 0.00.
Revenue703.00K
Gross Profit0.00
Operating Income0.00
Pretax Income10.31M
Net Income10.31M
EBITDA0.00
Earnings Per Share (EPS)0.00
Cash Flow
In the last 12 months, operating cash flow was -7.28M and capital expenditures 0.00, giving a free cash flow of -7.28M billion.
Operating Cash Flow-7.28M
Free Cash Flow-7.28M
Free Cash Flow per Share-0.66
Dividends & Yields
Brainstorm Cell Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.52
52-Week Price Change-21.57%
50-Day Moving Average0.69
200-Day Moving Average0.72
Relative Strength Index (RSI)66.99
Average Volume (3m)22.93K
Important Dates
Brainstorm Cell Therapeutics upcoming earnings date is May 18, 2026, Before Open (Confirmed).
Last Earnings DateApr 1, 2026
Next Earnings DateMay 18, 2026
Ex-Dividend Date―
Financial Position
Brainstorm Cell Therapeutics as a current ratio of 0.03, with Debt / Equity ratio of -2.02%
Current Ratio0.03
Quick Ratio0.03
Debt to Market Cap0.00
Net Debt to EBITDA0.00
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Brainstorm Cell Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Brainstorm Cell Therapeutics EV to EBITDA ratio is 0.00, with an EV/FCF ratio of -0.03.
EV to Sales0.25
EV to EBITDA0.00
EV to Free Cash Flow-0.03
EV to Operating Cash Flow-0.03
Balance Sheet
Brainstorm Cell Therapeutics has $5.00K in cash and marketable securities with $427.00K in debt, giving a net cash position of -$422.00K billion.
Cash & Marketable Securities$5.00K
Total Debt$427.00K
Net Cash-$422.00K
Net Cash Per Share-$0.04
Tangible Book Value Per Share$0.00
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 1466.15%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin1466.15%
Net Profit Margin1466.15%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Brainstorm Cell Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast58.09%